Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients.

Endrizzi B, Ahmed RL, Ray T, Dudek A, Lee P.

Dermatol Surg. 2013 Apr;39(4):634-45. doi: 10.1111/dsu.12049. Epub 2013 Feb 4.

PMID:
23379978
2.

Capecitabine for skin cancer prevention in solid organ transplant recipients.

Jirakulaporn T, Endrizzi B, Lindgren B, Mathew J, Lee PK, Dudek AZ.

Clin Transplant. 2011 Jul-Aug;25(4):541-8. doi: 10.1111/j.1399-0012.2010.01348.x. Epub 2010 Nov 2.

PMID:
21050273
3.

Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management.

Tessari G, Girolomoni G.

Dermatol Surg. 2012 Oct;38(10):1622-30. doi: 10.1111/j.1524-4725.2012.02520.x. Epub 2012 Jul 17. Review.

PMID:
22805312
4.

Capecitabine: a review.

Walko CM, Lindley C.

Clin Ther. 2005 Jan;27(1):23-44. Review.

PMID:
15763604
5.

Management of carcinoma of the skin in solid organ transplant recipients with oral capecitabine.

Endrizzi BT, Lee PK.

Dermatol Surg. 2009 Oct;35(10):1567-72. doi: 10.1111/j.1524-4725.2009.01277.x. Epub 2009 Jul 28. No abstract available.

PMID:
19681993
6.

Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid organ transplant recipients: a practical approach.

Ritchie SA, Patel MJ, Miller SJ.

Dermatol Surg. 2012 Oct;38(10):1604-21. doi: 10.1111/j.1524-4725.2012.02452.x. Epub 2012 May 30. Review.

PMID:
22646842
7.

[Patients with solid organ transplantation and skin cancer: determination of risk factors with emphasis in photoexposure and immunosuppressive regimen. Experience in a third level hospital].

Rodríguez-Acosta ED, Calva-Mercado JJ, Alberú-Gómez J, Vilatoba-Chapa M, Domínguez-Cherit J.

Gac Med Mex. 2015 Jan-Feb;151(1):20-6. Spanish.

8.

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P; Xeloda Colorectal Cancer Study Group.

J Clin Oncol. 2001 Nov 1;19(21):4097-106.

PMID:
11689577
9.

Sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients (SOTRs).

Asgari MM, Arron ST, Warton EM, Quesenberry CP Jr, Weisshaar D.

J Am Acad Dermatol. 2015 Sep;73(3):444-50. doi: 10.1016/j.jaad.2015.05.029. Epub 2015 Jun 30.

PMID:
26138646
10.

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.

Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C; X-ACT Study Group.

Ann Oncol. 2003 Dec;14(12):1735-43.

11.

Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy.

Willey A, Mehta S, Lee PK.

Dermatol Surg. 2010 May;36(5):652-8. doi: 10.1111/j.1524-4725.2009.01384.x. Epub 2009 Nov 4.

PMID:
19889154
12.

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R.

J Clin Oncol. 2001 Apr 15;19(8):2282-92.

PMID:
11304782
13.

Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study.

Ulrich C, Jürgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, Eberle J, Terhorst D, Sterry W, Stockfleth E.

Br J Dermatol. 2009 Nov;161 Suppl 3:78-84. doi: 10.1111/j.1365-2133.2009.09453.x.

PMID:
19775361
14.

Overview on non-melanoma skin cancers in solid organ transplant recipients.

Forchetti G, Suppa M, Del Marmol V.

G Ital Dermatol Venereol. 2014 Aug;149(4):383-7. Review.

PMID:
25068224
15.

Fibrohistiocytic tumors in a lung transplant patient taking oral capecitabine for nonmelanoma skin cancer chemoprevention.

Konda S, Patel VA, O'Bryan KW, Ratner D.

Dermatol Surg. 2014 Jul;40(7):807-10. doi: 10.1111/DSU.0000000000000039. No abstract available.

PMID:
24927001
16.
17.

Nonmelanoma skin cancer mortality (1988-2000): the Rhode Island follow-back study.

Lewis KG, Weinstock MA.

Arch Dermatol. 2004 Jul;140(7):837-42.

PMID:
15262694
18.

Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin.

Wollina U, Hansel G, Koch A, Köstler E.

J Cancer Res Clin Oncol. 2005 May;131(5):300-4. Epub 2004 Dec 24.

PMID:
15619125
19.

Facial resurfacing for nonmelanoma skin cancer prophylaxis.

Hantash BM, Stewart DB, Cooper ZA, Rehmus WE, Koch RJ, Swetter SM.

Arch Dermatol. 2006 Aug;142(8):976-82.

PMID:
16924046
20.

Immunosuppression and squamous cell carcinoma: a focus on solid organ transplant recipients.

Herman S, Rogers HD, Ratner D.

Skinmed. 2007 Sep-Oct;6(5):234-8. Review.

PMID:
17786101
Items per page

Supplemental Content

Write to the Help Desk